SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cure Pharmaceutical Holding Corp. – ‘8-K’ for 9/23/20

On:  Thursday, 9/24/20, at 5:00pm ET   ·   For:  9/23/20   ·   Accession #:  1477932-20-5584   ·   File #:  0-55908

Previous ‘8-K’:  ‘8-K’ on 7/28/20 for 7/27/20   ·   Next:  ‘8-K’ on 9/29/20 for 9/23/20   ·   Latest:  ‘8-K’ on 1/12/24 for 1/4/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/24/20  Cure Pharmaceutical Holding Corp. 8-K:5       9/23/20    1:27K                                    Discount Edgar/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     20K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  _________________________________________________________________

FORM 8-K

 _________________________________________________________________

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 23, 2020

 

CURE PHARMACEUTICAL HOLDING CORP.

(Exact name of registrant as specified in its charter)

 

Delaware

 

333-204857

 

37-1765151

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

1620 Beacon Place

Oxnard, California 93033

(Address of principal executive offices) (Zip Code)

 

(805) 824-0410

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

 

Item 5.07 - Submission of Matters to a Vote of Security Holders

 

Cure Pharmaceutical Holding Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on September 23, 2020. On July 28, 2020, the record date for determining stockholders entitled to vote at the Annual Meeting (the “Record Date”), there were 51,056,638 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) outstanding. Holders of 31,480,644 shares of Common Stock (representing 61.65% of the shares of Common Stock outstanding on the Record Date) were present or represented by proxy at the Annual Meeting, constituting a quorum. During the Annual Meeting, the stockholders of the Company voted on two proposals described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on August 7, 2020. The results for each matter voted on by the stockholders during the Annual Meeting were as follows:

 

Proposal 1: The stockholders of the Company elected Robert Davidson, William Yuan, Gene Salkind, M.D., Ruben King-Shaw, Jr., Joshua Held, Lauren Chung, Ph.D., Anya Goldin, and John Bell (collectively, the “Nominees”) to the Board of Directors, each for a one-year term ending at the Annual Meeting of Stockholders to be held in 2021 and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the Nominees were as follows:

 

Nominee

 

Term Expiring

 

For

 

 

Withheld

 

Robert Davidson

 

2021

 

 

26,113,406

 

 

 

82,315

 

William Yuan

 

2021

 

 

25,067,146

 

 

 

1,128,575

 

Gene Salkind, M.D.

 

2021

 

 

26,109,206

 

 

 

86,515

 

Ruben King-Shaw, Jr.

 

2021

 

 

25,197,346

 

 

 

998,375

 

Joshua Held

 

2021

 

 

25,065,195

 

 

 

1,130,526

 

Lauren Chung, Ph.D.

 

2021

 

 

26,115,706

 

 

 

80,015

 

Anya Goldin

 

2021

 

 

26,115,606

 

 

 

80,115

 

John Bell

 

2021

 

 

25,891,062

 

 

 

304,659

 

 

Broker Non-Votes: 5,284,923

 

Proposal 2: The stockholders of the Company ratified the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The results of the stockholders’ vote with respect to such ratification were as follows:

 

For

 

 

Against

 

 

Abstain

 

 

31,401,762

 

 

 

31,962

 

 

 

46,920

 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CURE PHARMACEUTICAL HOLDING CORP.

 

 

 

 

Dated: September 24, 2020

By:

/s/ Robert Davidson

 

 

 

Robert Davidson

 

 

 

Chief Executive Officer

 

 

 

3

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
12/31/2010-K
Filed on:9/24/20
For Period end:9/23/208-K
8/7/20DEF 14A
7/28/208-K
 List all Filings 
Top
Filing Submission 0001477932-20-005584   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:26:22.1pm ET